Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application. - Wikidata - awgldk - TriplyDB

Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.

Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.

http://www.wikidata.org/entity/Q34469627

about

Fibroblast Growth Factor Signaling in Metabolic Regulation A Network Map of FGF-1/FGFR Signaling System.Reprogramming the specificity of sortase enzymes.FGF-1 Triggers Pannexin-1 Hemichannel Opening in Spinal Astrocytes of Rodents and Promotes Inflammatory Responses in Acute Spinal Cord Slices.An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities.Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.Accelerated healing in NONcNZO10/LtJ type 2 diabetic mice by FGF-1.

P2860

Q26772751-DB9AF65B-2200-46D4-9F6E-4FFE5AF4BBB1 Q33562967-51B24ABC-F843-4B9D-961F-D8D45A7C1053 Q34218196-3109D6BB-6A46-41CD-B7FC-E6F3E45611A1 Q36840541-D7DD0A54-BAC8-48ED-9C6B-4E8AF12221BF Q38290536-BF6E042C-E41B-4BB0-BFF2-CCFB5701B8A5 Q42553159-A45BBAAE-8928-457E-863C-BC1B5D8D34FF Q47583813-AD97481A-A93D-447E-9EBC-82D4087010A6 Q53537715-6B3F91D4-97A5-4687-84A5-3EA15245C74F

P2860

Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.

http://www.wikidata.org/entity/Q34469627

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pharmacokinetic properties of ...... s for therapeutic application.

@ast

Pharmacokinetic properties of ...... s for therapeutic application.

@en

Pharmacokinetic properties of ...... s for therapeutic application.

@nl

type

label

Pharmacokinetic properties of ...... s for therapeutic application.

@ast

Pharmacokinetic properties of ...... s for therapeutic application.

@en

Pharmacokinetic properties of ...... s for therapeutic application.

@nl

prefLabel

Pharmacokinetic properties of ...... s for therapeutic application.

@ast

Pharmacokinetic properties of ...... s for therapeutic application.

@en

Pharmacokinetic properties of ...... s for therapeutic application.

@nl

P1433

Q34469627-4022F2BE-9D98-42D1-9315-F4FF4DF3DE6D

P1476

Q34469627-670C0755-D084-47FE-9410-AF957502F906

P2093

Q34469627-02683A5D-9991-4FB5-94E6-918FBAA69F47

Q34469627-1C974D66-6F32-4F13-A1B7-A4056454A508

Q34469627-1D1B167A-F73B-477D-B87A-FFD383C1B53B

Q34469627-6F726F7E-E4F2-48E6-9388-811FA715C57C

P2860

Q34469627-016F1F48-9362-4770-B5A4-D4FB1B30C7A9

Q34469627-0E915E98-53C2-4E34-84C7-1044B5E07E30

Q34469627-0FB3D0D2-BE56-4985-A640-CE3B8BE001C5

Q34469627-11C8BEE1-028A-40D2-9D02-47D303F5CA18

Q34469627-1207B23E-9CCE-420C-A0A2-27E12281355B

Q34469627-128332E1-69BA-4CE0-A775-68B6038B7640

Q34469627-1750B56A-4662-4F9C-BBEA-664AA69367C9

Q34469627-1D74B088-E0EC-48AB-BF6F-050F763046B8

Q34469627-3A94AEBB-EB31-48D5-8520-434FC7E1581B

Q34469627-453D59DC-7628-4064-9F01-55CA179239A7

P304

Q34469627-E46E4BD4-0E52-4D12-9F0B-403C2C3C1CF0

P31

Q34469627-9D6EB7D0-4CF8-4E79-8CFD-58CB0C450F5A

P356

Q34469627-DE98195A-898B-4009-BB6F-A32EF85E78B1

P407

Q34469627-5A39EC1D-CE5B-45D3-BF01-6650A8CB1937

P433

Q34469627-13ED5A9D-08A3-4579-BAA1-F3A09B5B3806

P478

Q34469627-D7D857D9-805E-4FB2-9BDF-518608D566A5

P50

Q34469627-75CA5C47-8773-4E32-BB44-FE74FD0107F2

P577

Q34469627-A2757123-C362-4338-BFC8-E36E43C7956D

P5875

Q34469627-9E988000-AF7C-4DC5-AEFF-ED67C5BDAC1A

P698

Q34469627-C0BCE16F-74CC-42C0-B201-08CA010C5734

P932

Q34469627-DAAB07B4-7C8A-42DC-97F5-D829423DD74C

P356

JOURNAL.PONE.0048210

P1433

P1476

Pharmacokinetic properties of ...... s for therapeutic application.

@en

P2093

Joseph P Babcock

http://www.w3.org/2001/XMLSchema#string

Kathleen M Harper

http://www.w3.org/2001/XMLSchema#string

Sachiko I Blaber

http://www.w3.org/2001/XMLSchema#string

Xue Xia

http://www.w3.org/2001/XMLSchema#string

P2860

FGF-21 as a novel metabolic regulator.

Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a β-trefoil

Structural bases of stability-function tradeoffs in enzymes

Accommodation of a highly symmetric core within a symmetric protein superfold

Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions

The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1

A polypeptide "building block" for the β-trefoil fold identified by "top-down symmetric deconstruction"

X-ray crystal structure of human acidic fibroblast growth factor

Calculation of protein extinction coefficients from amino acid sequence data

beta-Trefoil fold. Patterns of structure and sequence in the Kunitz inhibitors interleukins-1 beta and 1 alpha and fibroblast growth factors

P304

e48210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0048210

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232975617

http://www.w3.org/2001/XMLSchema#string

P698

23133616

http://www.w3.org/2001/XMLSchema#string

P932

3486806

http://www.w3.org/2001/XMLSchema#string